Synaptogenix Announces Publication of Peer-Reviewed Scientific Paper Demonstrating Improved Cognition of Byrostatin-1 Compared to Baseline in Patients with Advanced Alzheimer’s Disease

NEW YORK, February 1, 2022 /PRNewswire/ — Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), a clinical-stage biopharmaceutical company developing regenerative therapies for neurodegenerative disorders, today announced that its peer-reviewed scientific manuscript titled “Placebo-Controlled Bryostatin Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer’s Disease (“AD”) in the Absence of Memantine” was published in the Alzheimer’s Disease Journal. The article documents evidence from two placebo-controlled trials that bryostatin-1 improved cognition from baseline in patients with advanced AD.

“Rigorous statistical analyses, including a pooled test of identical pre-specified cohorts in two separate trials, revealed a highly significant (pDaniel Alcon, MD, President and Scientific Director. “Importantly, we believe that the peer-reviewed data in our manuscript has provided further rationale for our continued support of National Institutes of Health (“NIH”) grants for our current phase. 2b clinical test.”

Alan TuchmanMD, President and CEO, said, “The power of these results, reinforced by the appropriate pooling of pre-specified cohorts, encourages us to believe that our six-month trial will confirm the effective treatment of bryostatin-1 against the underlying degenerative progression of Alzheimer’s disease – one argue that other therapeutic strategies have been unproven to date.”

About Synaptogenix, Inc.

Synaptogenix is ​​a clinical-stage biopharmaceutical company discovering novel restorative therapies for patients with life-altering neurodegenerative diseases and developmental disabilities. Synaptogenix is ​​currently conducting a National Institutes of Health-supported Phase 2b clinical trial of its lead therapeutic candidate Bryostatin-1 in patients with moderate to severe Alzheimer’s disease. In addition to Alzheimer’s disease, preclinical studies have demonstrated bryostatin-1’s regenerative mechanisms of action for fragile X syndrome, a rare disease, and the United States Food and Drug Administration has granted orphan drug designation for this indication. Other potential indications include multiple sclerosis (“MS”), stroke, and traumatic brain injury. Bryostatin has already been tested in over 1,500 people in cancer studies, creating an extensive safety database that will further inform clinical trial design.

Forward-looking statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the continued development of the use of bryostatin-1 for Alzheimer’s disease, fragile X and other dementias. These forward-looking statements are subject to risks and uncertainties and other influences, many of which are beyond the Company’s control. There can be no assurance that the clinical program for Bryostatin-1 will successfully demonstrate safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive approval regulation or will be successfully marketed. . Actual results and the timing of certain events and circumstances may differ materially from those described in the forward-looking statements due to these risks and uncertainties. Other factors that could influence or cause actual results to differ materially from expected or desired results may include, but are not limited to, the Company’s inability to obtain adequate financing, the length of time associated with drug development and the related insufficient cash flow and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand its business, significant government regulation of the pharmaceutical and healthcare industry , lack of product diversification, availability of the Company’s raw materials, existing or increased competition, stock volatility and illiquidity, and the Company’s inability to implement its business plans or strategies . These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Investor and media contact:

[email protected]

Robert Weinstein
Financial director
Synaptogenix, Inc.
[email protected]

SOURCE Synaptogenix, Inc.

Jacob L. Thornton